Switching from infliximab to biosimilar may be safe and effective

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

Takeaway

  • CT-P13 demonstrated noninferiority in NOR-SWITCH, a switching study from infliximab, but remains unstudied for individual indications or multiple switches.

Why this matters

  • TNF inhibitors such as infliximab are effective in a range of autoimmune diseases, but are expensive...